Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
- Revenue in USD (TTM)0.00
- Net income in USD-95.71m
- Incorporated2017
- Employees42.00
- LocationBiomea Fusion Inc1599 Industrial RoadSAN CARLOS 94070United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuo Therapeutics Inc | 2.61m | -2.43m | 77.25m | -- | -- | -- | -- | 29.58 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| ImageneBio Inc | 0.00 | -46.14m | 77.27m | 15.00 | -- | 0.5526 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 78.98m | 4.00 | -- | 0.7767 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 80.76m | 19.00 | -- | 4.13 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 80.94m | 44.00 | -- | 1.17 | -- | 28.70 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 84.43m | 213.00 | 36.48 | 20.25 | 21.23 | 1.45 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 85.87m | 31.00 | -- | 15.95 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 87.59m | 56.00 | -- | 1.09 | -- | 461.00 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 88.38m | 42.00 | -- | 4.76 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 89.07m | 67.00 | -- | 2.83 | -- | 127.61 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 91.26m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Incannex Healthcare Inc | 12.00k | -47.87m | 93.17m | 12.00 | -- | 1.22 | -- | 7,764.11 | -0.9375 | -0.9375 | 0.0001 | 0.2215 | 0.0003 | -- | 0.0015 | 1,000.00 | -101.03 | -155.80 | -114.13 | -186.20 | -- | -- | -398,933.30 | -6,230.96 | -- | -43.84 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 94.13m | 4.00 | -- | 6.14 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 95.60m | 35.00 | -- | 3.08 | -- | 21.77 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 98.18m | 106.00 | -- | 0.7598 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 98.87m | 25.00 | -- | 2.71 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
Data as of Feb 13 2026. Currency figures normalised to Biomea Fusion Inc's reporting currency: US Dollar USD
31.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.62m | 10.71% |
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 3.75m | 5.27% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.60m | 3.65% |
| Aisling Capital Management LPas of 31 Dec 2025 | 2.05m | 2.88% |
| Heights Capital Management, Inc.as of 30 Sep 2025 | 1.44m | 2.02% |
| Woodline Partners LPas of 30 Sep 2025 | 1.30m | 1.83% |
| Marshall Wace LLPas of 31 Dec 2025 | 1.16m | 1.63% |
| Cormorant Asset Management LPas of 22 Oct 2025 | 950.00k | 1.34% |
| Fideuram Asset Management SGR SpAas of 31 Dec 2025 | 631.47k | 0.89% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 620.56k | 0.87% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
